JP Morgan Chase’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-30,000
| Closed | -$1.64M | – | 7743 |
|
|
2026
Q1 | $1.64M | Hold |
30,000
| – | – | ﹤0.01% | 4259 |
|
|
2025
Q4 | $1.78M | Buy |
+30,000
| New | +$1.63M | ﹤0.01% | 4166 |
|
|
2024
Q3 | – | Sell |
-18,300
| Closed | -$1.51M | – | 7422 |
|
|
2024
Q2 | $1.51M | Buy |
+18,300
| New | +$1.52M | ﹤0.01% | 3993 |
|
|
2023
Q3 | – | Sell |
-53,900
| Closed | -$4.67M | – | 7470 |
|
|
2023
Q2 | $4.67M | Buy |
53,900
+27,600
| +105% | +$2.6M | ﹤0.01% | 2922 |
|
|
2023
Q1 | $2.56M | Hold |
26,300
| – | – | ﹤0.01% | 3359 |
|
|
2022
Q4 | $2.72M | Buy |
+26,300
| New | +$2.47M | ﹤0.01% | 3326 |
|
|
2022
Q3 | – | Sell |
-50,000
| Closed | -$4.14M | – | 6466 |
|
|
2022
Q2 | $4.14M | Buy |
50,000
+49,800
| +24,900% | +$3.97M | ﹤0.01% | 2952 |
|
|
2022
Q1 | $15K | Buy |
+200
| New | +$16.7K | ﹤0.01% | 6121 |
|
|
2021
Q2 | – | Sell |
-50,000
| Closed | -$3.78M | – | 6347 |
|
|
2021
Q1 | $3.78M | Sell |
50,000
-78,800
| -61% | -$6.44M | ﹤0.01% | 3212 |
|
|
2020
Q4 | $11.3M | Buy |
128,800
+38,300
| +42% | +$3.04M | ﹤0.01% | 2111 |
|
|
2020
Q3 | $6.88M | Buy |
90,500
+50,000
| +123% | +$5.06M | ﹤0.01% | 2314 |
|
|
2020
Q2 | $5M | Buy |
+40,500
| New | +$4.03M | ﹤0.01% | 2459 |
|
|
2020
Q1 | – | Sell |
-27,000
| Closed | -$2.28M | – | 5309 |
|
|
2019
Q4 | $2.28M | Buy |
27,000
+12,000
| +80% | +$906K | ﹤0.01% | 3293 |
|
|
2019
Q3 | $1.01M | Sell |
15,000
-105,000
| -88% | -$8.09M | ﹤0.01% | 3824 |
|
|
2019
Q2 | $10.1M | Buy |
+120,000
| New | +$10.3M | ﹤0.01% | 2103 |
|
|
2019
Q1 | – | Sell |
-289,300
| Closed | -$24.6M | – | 5765 |
|
|
2018
Q4 | $24.6M | Buy |
289,300
+180,000
| +165% | +$17.1M | 0.01% | 1326 |
|
|
2018
Q3 | $10.6M | Sell |
109,300
-700
| -0.6% | -$69.9K | ﹤0.01% | 2156 |
|
|
2018
Q2 | $10.4M | Buy |
110,000
+60,000
| +120% | +$5.25M | ﹤0.01% | 2117 |
|
|
2018
Q1 | $4.05M | Hold |
50,000
| – | – | ﹤0.01% | 2755 |
|
|
2017
Q4 | $4.46M | Buy |
+50,000
| New | +$4.35M | ﹤0.01% | 2771 |
|
|
2017
Q1 | – | Sell |
-40,000
| Closed | -$3.31M | – | 5048 |
|
|
2016
Q4 | $3.31M | Buy |
+40,000
| New | +$3.44M | ﹤0.01% | 2749 |
|
|
2016
Q3 | – | Sell |
-50,000
| Closed | -$3.89M | – | 4542 |
|
|
2016
Q2 | $3.89M | Buy |
+50,000
| New | +$4.25M | ﹤0.01% | 2442 |
|
Other funds holding BMRN
VPC
JP Morgan Chase's BMRN Position: Q2 2026 in Review
JP Morgan Chase increased its BioMarin Pharmaceuticals (BMRN) stake by 25% in Q2 2026, buying an estimated $7.49M and bringing the position to 694,550 shares worth $40.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1631.
JP Morgan Chase first reported a position in BMRN in Q2 2013 and has held it in 53 quarters since. The position peaked at $590M in Q4 2015. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.
- JP Morgan Chase held 694,550 shares of BioMarin Pharmaceuticals worth $40.6M as of Q2 2026.
- JP Morgan Chase bought 136,714 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $7.49M.
- BioMarin Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1631 holding.
- JP Morgan Chase first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- JP Morgan Chase's BioMarin Pharmaceuticals position peaked at $590M in Q4 2015.
- 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.